Investing in Life Science
Set in vibrant Stockholm, the finance capital of Sweden, this boutique investor event connects regional life science leaders looking for strategic partnerships with investors eager to explore opportunities across all-stages.
From emerging medical breakthroughs to scale-ups ready for global market expansion, this exclusive event will showcase the full spectrum of Nordic innovation.
Join us in September to engage with industry experts and forge valuable connections with fellow investors, as you tap into the latest therapeutic breakthroughs in a dynamic, collaborative environment.
On Stage
Event Partners
Speakers
Everett Kamin
Healthcare CIO & Board Director at Gemini Capital Partners.
CIO & Advisory Board Member at Silverstein Dream Foundation
Impact Investment & Board Advisor at Macmillan Cancer Support
Svana Gunnarsdóttir
Managing Partner
Frumtak Ventures
Stina Wallmark
Investment Director Life Sciences
Voima Ventures
Karin Leire
Investment Director
Segulah Medical Acceleration
Andreas Lindblom
Managing Partner
Sciety
Kristofer Klerfalk
Managing Partner
Life Science Invest
Nina Rawal
Investment Committee Member at We Venture Capital
Founder at Emerging Health Ventures
Ulrica Slåne Bjerke
CIO
Arctic Aurora LifeScience
Laurent Pacheco
Managing Partner at IFOAH
Partner at Solas BioVentures
Maria Nyåkern
Founder & Investor
Nyakern Nexus Investments
Hugo Mörse
Partner at Bonit Capital
Managing Director at Leksell Social Ventures
Jan Erik Smith
Partner
Gobia Enterprises
Fredrik Andersson
CEO
Bonnier Healthcare
Melissa Simon
Partner
Wieland Capital
Laurens de Vries
Life Science Investor
Opdorp finance
Company showcases
Experience dynamic, concise presentations from pioneering life science innovators, showcasing cutting-edge advancements and transformative trends shaping the industry’s future. Engage directly with these trailblazers in interactive Q&A sessions, gaining exclusive insights to inform your strategic decisions. Don’t miss this premier opportunity to connect, learn, and invest in the next wave of life science innovation.
Panel Discussions
Building giants or selling science? The Nordic capital agenda
The Nordics are undisputedly a global powerhouse for innovation and early-stage science. Yet, the region often struggles to scale these innovations into independent, global industrial players. Too often, our most promising assets are acquired by international pharma giants before they reach their full commercial potential.
In this high-level panel, we bring together the region’s heavyweight investors, managing the largest pools of capital, to discuss the strategic roadmap for 2026 and beyond. Do we have the financial depth and risk appetite to back companies ”all the way,” or is the early-exit model a necessity? We debate the power of syndication, the need for larger ticket sizes, and what it will actually take for Nordic Venture Capital to build the next Novo Nordisk.
Panelists includes:
Andreas Lindblom, Managing Partner, Sciety
Ulrica Slåne Bjerne, CIO, Arctic Aurora LifeScience
Max Odlander, Partner, HealthCap
Everett Kamin, CIO, Gemini Capital Partners & CIO, Silverstein Dream Foundation
All moderated by: Nina Rawal, Investment Committee Member, We Venture Capital
Funding the Future of Health: A Nordic Investor Perspective
What does the future of healthcare look like through the lens of those who fund it? Join a panel of premier Nordic investors as they explore the next wave of MedTech breakthroughs. The discussion will delve into where the region’s biggest investment opportunities lie, how geopolitical shifts impact funding timelines, and how we turn brilliant Scandinavian science into sustainable, global businesses.
Panelists includes:
Svana Gunnarsdóttir, Co-founder & Managing Partner, Frumtak Ventures
Karin Leire, Investment Manager, Segula Medical Acceleration
Kristofer Klerfalk, Managing Partner, Life Science Invest
Fredrik Andersson, CEO, Bonnier Healthcare Sweden
All moderated by: Stina Wallmark, Investment Director, VOIMA Ventures
A Premier Venue
BioStock will host Investing in Life Science – From Seed to Success at the prestigious IVA Conference Centre, nestled in the heart of Stockholm’s historic quarters. This iconic venue seamlessly blends the city’s timeless charm with state-of-the-art facilities, creating an inspiring backdrop for transformative connections. Engage in unparalleled networking and collaboration with leading innovators, investors, and industry experts in a sophisticated setting designed to spark innovation and drive the future of life science.
📍Grev Turegatan 16
Testimonials
The venue and organization was top tier, quite impressed. Great pitches and generous pauses for mingling with a highly relevant audience
Great presentations by interesting companies and investors, nice networking opportunities.
Professional, an event that will grow due to arranger/host qualities
See our latest Biostock event
About our event partners
DNB Carnegie | Back Bay
DNB Carnegie | Back Bay is a unique integrated strategy and corporate and investment banking solution for global and emerging life science and healthcare companies.
We combine scientific and strategic expertise with financing origination and execution to support healthcare companies of all sizes through each stage of growth—from chemistry to commercialization. Learn more and subscribe for our market updates: www.bblsa.com/dnb-carnegie-back-bay-partnership
Nasdaq
With more than 90 pct. of all US biotech, pharma & life science companies listed on Nasdaq, we know how to match savvy investors with trail-blazing inventors.
We are here to support your ideas and the next steps to a public offering that keeps you in control while raising capital to ignite your ambition. By the way, if you want to keep your ambition closer to home, Nasdaq in the Nordic is the leading hub for listed biotech and health care companies in Europe, with strong support from investors and innovation communities across the region.
How to join the Nasdaq family? – Read more here.
Potter Clarkson
Potter Clarkson is one of Europe’s leading full-service IP law firms.
Our sole objective is to help innovators and investors maximise the value of their business or investments by identifying, protecting, exploiting, and enforcing the required IP rights anywhere in the world.
With regards to biotechnology and the life sciences, our team is one of Europe’s largest. We are fiercely proud of our reputation as the European IP firm of choice for clients of all sizes, from ambitious start-ups and SMEs through to Big Pharma.
Having worked alongside investors in the Nordics, Germany, and the UK for decades we also know to deliver the comprehensive and commercial view of the IP in an investment required to support the best investment decisions.
